Hims & Hers' shift to branded obesity drugs drives wider quarterly loss
By Sneha S K and Amina Niasse NEW YORK, Aug 10 (Reuters) - Hims & Hers Health posted a wider-than-expected second-quarter loss on Monday as the telehealth company's shift to branded weight-loss drugs drove up costs, sending its shares down 6% in extended trading.